{"id":"NCT02269917","sponsor":"Janssen R&D Ireland","briefTitle":"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants","officialTitle":"A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2017-02","completion":"2020-10","firstPosted":"2014-10-21","resultsPosted":"2018-11-09","lastUpdate":"2021-12-09"},"enrollment":1149,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Human Immunodeficiency Virus Type 1"],"interventions":[{"type":"DRUG","name":"D/C/F/TAF","otherNames":[]},{"type":"DRUG","name":"Boosted Protease Inhibitor (bPI)","otherNames":[]},{"type":"DRUG","name":"FTC/TDF","otherNames":[]}],"arms":[{"label":"Experimental Treatment Regimen","type":"EXPERIMENTAL"},{"label":"Current Treatment Regimen","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed (human immunodeficiency virus type 1 ribonucleic acid \\[HIV-1 RNA\\] concentrations less than \\[\\<\\] 50 copies per milliliter \\[copies/mL\\]) HIV-1 infected participants.","primaryOutcome":{"measure":"Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48","timeFrame":"Through Week 48","effectByArm":[{"arm":"D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])","deltaMin":2.5,"sd":null},{"arm":"Control (Baseline to Switch)","deltaMin":2.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":79,"countries":["United States","Belgium","Canada","France","Poland","Puerto Rico","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["34100149","33528318","31516033","31464642","28993180"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":114,"n":763},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Diarrhoea","Back pain","Headache"]}}